trimetrexate has been researched along with Chagas Disease in 2 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Chagas Disease: Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schormann, N | 1 |
| Velu, SE | 1 |
| Murugesan, S | 1 |
| Senkovich, O | 2 |
| Walker, K | 1 |
| Chenna, BC | 1 |
| Shinkre, B | 1 |
| Desai, A | 1 |
| Chattopadhyay, D | 2 |
| Bhatia, V | 1 |
| Garg, N | 1 |
2 other studies available for trimetrexate and Chagas Disease
| Article | Year |
|---|---|
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase.
Topics: Chagas Disease; Computer Simulation; Crystallization; Crystallography, X-Ray; Enzyme Inhibitors; Fol | 2010 |
Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.
Topics: Animals; Chagas Disease; Drug Combinations; Folic Acid Antagonists; Glucuronates; Humans; Multienzym | 2005 |